Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers
Abstract
Case (description) the patient is a 20 years old male smoker, who was diagnosed with type 2 diabetes mellitus in 2006. Due to the inadequate response to the previously established treatment, the pharmacotherapy was modified by introducing exenatide (up to 10 μg, twice daily) instead of insulin glargine, but maintaining the treatment with the diuretic and angiotensin II receptor antagonist drugs. Two months later, the patient exhibited a very important intolerance to exenatide (continuous nausea, vomiting, and dehydration), finally leading to ischemic acute renal failure. When the angiotensin II receptor antagonist and exenatide were suspended, a very rapid recovery of renal function was observed. Conclusion ischemic acute renal failure is supposed to be the consequence of the extracellular volume contraction caused by exenatide (the result of continuous nausea and vomiting). This adverse effect could be caused by the co-administration of diuretics and angiotensin II receptor antagonists.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Initial case reports suggested that GLP-1RA treatment could cause acute kidney injury in some patients.
“Initial case reports suggested that GLP-1RA treatment could cause acute kidney injury (AKI) in some patients”
From Safety of Semaglutide (2021) · cites this paper as [114]
With GLP-1RA, case reports and adverse event database studies first signaled acute kidney injury, pancreatitis, pancreatic cancer and thyroid cancer.
“With GLP-1RA, these encompassed AKI, pancreatitis, pancreatic cancer and thyroid cancer”
From Safety of Semaglutide (2021) · cites this paper as [114]
The citation lists haven’t been fetched yet
References 11 · Cited by 44
- Authors
- López-Ruiz, A., Peso-Gilsanz, C., Meoro-Avilés, A., Soriano-Palao, J., Andreu, A., Cabezuelo, J., & Arias, J. L.
- Affiliations
- Hospital Universitario Reina Sofía (ES)
- Universidad de Granada (ES)
- Corresponding author
- López-Ruiz, Alfonso
- Venue
- Pharmacy World & Science
- Published
- 2010-08-05
- Volume
- 32
- Issue
- 5
- Pages
- 559-561
- ISSN
- 0167-6555 (ISSN-L)
- 0928-1231
- 1573-739X
- OpenAlex
- W2001660813
- Cited by
- 44
- References
- 11
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2022: 1 · 2021: 2 · 2020: 2 · 2017: 5 · 2016: 5 · 2014: 6 · 2013: 7 · 2012: 5
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmacy World & Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- acute kidney injury, exenatide, diuretics, angiotensin receptor blockers, drug-drug interactions, type 2 diabetes, nausea and vomiting, adverse drug reactions, renal function recovery
- MeSH terms
- Exenatide, Diabetes Mellitus, Type 2, Diuretics, Drug Interactions, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Male, Peptides, Venoms, Young Adult, Angiotensin Receptor Antagonists, Acute Kidney Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review